AFMD - Affimed: Wholly-Owned Pipeline Programs Support A Long-Term Investment

• Affimed's wholly-owned pipeline programs continue to report impressive clinical data that supports a long-term investment. I believe is Affimed is trailblazing on a new approach in oncology.
• The company's three-pronged approach of testing their products as a monotherapy, NK combo, and I-O combo, has revealed impressive results.
• In my previous AFMD article, I discussed why the company's partnerships were vital to the investment thesis. Now, I believe Affimed's wholly-owned candidates will be the primary driver.
• I discuss my plans for adding onto my undersized position while still managing to book some profits and reduce downside risk.

For further details see: